New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
09:17 EDTDYSLDynasil awarded $2.1M contract from Department of Homeland Security
Dynasil Corporation of America's RMD Research subsidiary has been awarded contracts totaling $2.1M from the Department of Homeland Security's Domestic Nuclear Detection Office. These contracts will advance the government's research and development initiatives focused on the identification of illicit nuclear materials.
News For DYSL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2015
09:03 EDTDYSLDynasil Corporation to supply crystal components to security equipment provider
Subscribe for More Information
August 18, 2015
15:49 EDTDYSLDynasil unit announces conversion of patent application
Dynasil Corporation of America announced the conversion of Xcede Technologies, provisional U.S. Patent application claiming novel tissue patch systems, methods and compositions. Xcede Technologies, a subsidiary of Dynasil Biomedical Corp, is based in Rochester, MN and began operations in October 2013 following a technology transfer from DBM. Xcede is committed to the development and manufacturing of innovative hemostatic and sealant products for surgical application. Xcede's first product, currently under development, is a resorbable hemostatic patch to be used when conventional techniques are inadequate or impractical during general or cardiovascular surgery. The conversion of the provisional patent describes the combination of chemistry, coating and drying process that are utilized in coating the resorbable Xcede Patch fibrin backing. The method described uses a series of steps in which the coating is applied to the substrate which in the end provides a hemostatic patch that has high tensile strength in combination with high adhesive properties and maintained elasticity. The coated product described within this patent has the ability to seal a wide range of surgical bleeding complications, but the high strength characteristics provide the exciting possibility of sealing high pressure bleeding that currently has not been addressed in the market place."We believe Xcede continues to represent a hidden gem in the assets of Dynasil. We are encouraged by Xcede's recent technology developments and the potential to revolutionize the multi-billion dollar global fibrin sealants and hemostasis markets," said Peter Sulick, Chairman and CEO of Dynasil.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use